ACR Best Abstracts - Day 3 The last day was jammed with important reports and research including the late breaking abstracts. These were some of our favorites. #ACR22 https://t.co/vUrxBTF3Wj https://t.co/QKpTjyFfxt

• https://bit.ly/3g8j9Ry

#ACR22 final plenary session 10 week study outcomes of Philly vs Placebo to be reported #rheumpix @RheumNow https://t.co/BradH2Ty70

Can you put a bit of morphine intraarticularly inside an osteoarthritic knee and make it better? Cute idea, no bingo. I get that we're chasing better symptomatic solutions, but... Don't do this. ABST1833 #ACR22 @RheumNow https://t.co/pvsGx93eoU

Erosive OA: have we got anything disease-modifying? Not much right now (read: nothing) Denosumab 60mg q3mo for bone remodelling? radiographic change, erosive jt development: real improvement pain, function: zip at 48w, some at 96w? Def worth more study! ABSTL05 #ACR22 @RheumNow https://t.co/Yo9u5BlYYJ

PAN relapse risk ⬆️ in: 👉severe GI involvement 🧓>65y/o 👉skin necrotic lesions PAN ⬆️ mortality wt: 👉AKI 🧓>65y/o 👉necrotic purpura 👉secondary PAN Abst#2232 @RheumNow #ACR22

Abstr #2196- COVID-19 outcomes in IMID dx in large US Hospital vs Pre-Omicron - ↑ COVID + rate (21.9% vs 7.9%) - ↓ hospitalized (0.8% vs 3%) & death (1.8% vs 4.5%) - Hospitalization & death > gen pop both pd. -Age & comorbidities assoc w worse outcomes @RheumNow #ACR22

Biosimilar multi-switching in RA: is it an issue? Switching back & forth between originator & biosimilar should create ideal conditions for immunogenicity or anti-drug Ab This study: multi-switching vs no switching No issues at all Switch away in RA! ABST1589 #ACR22 @RheumNow https://t.co/pGBF2BHp7y

We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/ygfYol5Z3f

ACR2022 Topic Panels https://t.co/5gMfFS8maR

• https://twitter.com/i/broadcasts/1yNxaNEQygRKj